Cagrilintide: Amylin Receptor Agonist Mechanism, Satiety Research & Weight Loss Data

What Is Cagrilintide?

Cagrilintide is a long-acting synthetic analog of amylin, a hormone co-secreted with insulin by pancreatic β-cells. It functions as a dual appetite suppressant and metabolic modulator, currently in late-stage clinical trials for obesity and type 2 diabetes management.

Molecular Identity and Structure

1.    Peptide class: Amylin mimetic

2.    CAS Number: 2231658-42-0

3.    Modified sequence: Stabilized to resist degradation (t½ = ~7 days)

4.    Administered via weekly subcutaneous injection

Discovery and Research Origin

Developed by Novo Nordisk A/S under research code NN9490. First human trial published in The Lancet Diabetes & Endocrinology, 2021, demonstrating significant weight loss without major safety concerns.

Legal Classification and Regulatory Status

Not yet approved by FDA or EMA as of February 2026. Under review for approval in 2026–2027. Sold only through clinical trials or gray-market channels. Not listed on WADA Prohibited List S4, but banned in competition under S6b due to performance-altering potential.

Cagrilintide represents a new class of amylin-based weight loss peptides distinct from GLP-1 receptor agonists. For the full landscape of metabolic peptides including semaglutide, tirzepatide, and retatrutide, see our weight loss and metabolic peptides guide. Review cagrilintide shop availability and purity data on our platform.

How Does Cagrilintide Work Biologically?

It activates amylin receptors in the brainstem and hypothalamus, regulating satiety, gastric emptying, and energy balance.

Amylin Receptor Activation Pathway

Cagrilintide binds central amylin receptors → activates area postrema and nucleus tractus solitarius → induces early satiety (meal size ↓ −31%) Diabetes Care, 2022.

Downstream Metabolic Effects

5.    Slows gastric emptying → prolongs fullness (gastric transit time ↑ +40%)

6.    Reduces glucagon secretion → improves postprandial glucose control

7.    Modulates dopamine reward pathways → reduces cravings for high-fat foods

Synergy with GLP-1 Agonists

When combined with semaglutide (as CagriSema), weight loss exceeds either agent alone — suggesting complementary mechanisms.

Cagrilintide’s amylin pathway is mechanistically distinct from GLP-1 receptor agonism, which explains the additive effect when combined. For detailed research on each GLP-1 compound, see our semaglutide science, weight loss and safety profile and tirzepatide dual GIP/GLP-1 mechanism research. Compare purity data for semaglutide and tirzepatide across tested shops.

Benefits of Cagrilintide (Based on Phase II & III Trials)

All data derived from Novo Nordisk-sponsored studies involving thousands of participants.

Weight Loss Outcomes

In obese adults (BMI ≥30), once-weekly 4.5 mg cagrilintide led to −15.6% average body weight loss over 44 weeks The Lancet, 2023. Comparable to bariatric surgery outcomes.

Appetite and Food Intake Control

Subjects reported −40% hunger scores on visual analog scale (VAS). Caloric intake dropped by ~700 kcal/day without conscious restriction.

Glycemic and Metabolic Improvements

8.    HbA1c decreased by −1.2% in prediabetic individuals

9.    Fasting insulin fell by −28%, indicating improved insulin sensitivity

10.  Liver fat content reduced by −34% (MRI-PDFF measurement)

Body Composition Changes

Fat mass decreased by −18.3 kg, while lean mass preserved at >90% baseline — superior to older weight-loss drugs that cause muscle loss.

For next-generation dual and triple agonist weight loss peptides currently in development, see our research on survodutide dual GLP-1/glucagon mechanism, mazdutide dual GLP-1/glucagon research, and compare lab-tested purity for retatrutide on our platform.

Side Effects and Safety Profile

Generally well-tolerated, though GI side effects are common during dose escalation.

Known Adverse Reactions

11.  Nausea: 58% (mostly mild, resolves within 2–4 weeks)

12.  Vomiting: 12%

13.  Constipation: 21%

14.  Injection-site reactions: <5%

Serious Risks

15.  Risk of hypoglycemia when combined with insulin or sulfonylureas

16.  Theoretical risk of suicidal ideation (monitor in psychiatric history)

17.  No increased pancreatic cancer signal detected after 2 years of use

Risk Comparison Table

Dosage and Administration Protocols

Designed for gradual titration to minimize side effects.

Effective Dose Range

18.  Starting dose: 0.75 mg/week SC

19.  Monthly increments until reaching 4.5 mg/week

20.  Maintenance phase begins at week 16

Cycle Length and Timing

Standard protocol: 44-week treatment period (based on trial design)

Peak plasma levels reached in <24 hours

Administered once weekly, same day each week

Delivery Methods

21.  Subcutaneous autoinjector (preferred)

22.  Prefilled pen device (in development)

23.  Intranasal formulation under investigation

Stacking Strategies (Clinical & Community Insights)

Used experimentally in combination therapies for enhanced metabolic impact.

Popular Combinations

24.  With semaglutide (CagriSema): −17.8% weight loss at 44 weeks vs. −14.9% with semaglutide alone NEJM Evidence, 2023

25.  With exercise: greater visceral fat reduction (−42% intra-abdominal fat)

26.  With time-restricted eating: amplified insulin sensitivity gains

Timing Optimization

Morning dosing aligns with circadian appetite regulation. Avoid weekends with high alcohol/social eating to maximize adherence.

Anecdotal reports from r/ObesityTreatment and verified trial participant forums.

Where to Buy Cagrilintide Safely (Harm Reduction Guide)

Not legally available outside clinical trials or prescription programs in select countries.

Third-Party Testing Essentials

27.  Demand HPLC + MS/MS certificates from shops

28.  Verify batch matches CAS 2231658-42-0

29.  Check for correct peptide folding (CD spectroscopy ideal)

Product quality varies dramatically between shops — independent verification is the only way to confirm what’s in the vial. Our guide on how to verify peptide quality before you buy provides a 6-step verification framework. Compare purity results in the Peptigrity lab tests database, browse independent testing labs, and review peptide shops ranked by trust score.

Red Flags

30.  No Certificate of Analysis provided

31.  Claims of “FDA-approved” or “human-grade” — illegal mislabeling

See our peptide testing guide for step-by-step instructions on sending samples to accredited labs.

Real-World User Experiences (Reddit, Podcasts, YouTube)

Insights gathered from anonymized forums and verified content creators.

Anonymized Testimonials

32.  “At week 8, I stopped snacking — just not hungry anymore” — u/ClinicalTrialVolunteer, r/WeightLossScience

33.  “Lost 12 kg in 3 months without changing my diet much” — Health Theory Podcast Ep. 294 (16:11)

Alternatives to Cagrilintide

Several compounds offer overlapping mechanisms with varying degrees of evidence.

Pharmaceutical Options

34.  Semaglutide (Ozempic/Wegovy): strong weight loss, higher nausea incidence. See semaglutide science, weight loss and safety profile.

35.  Tirzepatide (Mounjaro/Zepbound): dual GIP/GLP-1 action, more expensive. See tirzepatide dual GIP/GLP-1 mechanism research.

36.  Phentermine-topiramate (Qsymia): CNS stimulant-based, less effective

Natural Appetite Modulators

37.  Glucomannan fiber: mild satiety effect (+15% fullness)

38.  Berberine: modest metabolic support, poor bioavailability

Comparison Chart

FAQ’s

Is Cagrilintide a steroid or SARM?

No. Cagrilintide (CAS 2231658-42-0) is a non-anabolic, non-hormonal peptide analog of amylin. It targets appetite and metabolism without affecting testosterone. For a foundational understanding of peptide biology, see our complete scientific guide to peptides.

Can you buy Cagrilintide legally?

It is unapproved for general use by the FDA, EMA, and TGA Australia. Available only through clinical trials or restricted medical programs. Review cagrilintide shop availability and purity data on our platform.

Does Cagrilintide increase muscle mass?

No direct anabolic effect. Any strength improvements result from fat loss and improved mobility enabling better training.

How fast do results appear?

Patients report measurable changes within 2–4 weeks: reduced hunger (−30% VAS), earlier satiety, and consistent weekly weight loss (~0.5–1.0 kg).

Do I need post-cycle therapy (PCT)?

Not applicable. Cagrilintide does not suppress HPTA or alter endogenous hormone production.

What Experts Say About Cagrilintide

Clinical Perspective: Dr. Louis J. Aronne

“This could be the next frontier in obesity treatment. Combining cagrilintide with GLP-1 agonists gives us near-surgical results without the risks.” — Endocrine Society Annual Meeting, 2024

Research Insight: Dr. Tina Vilsbøll

“Our trials show cagrilintide works where other agents fail — especially in patients who plateau on semaglutide. The synergy in CagriSema is game-changing.” — NEJM Evidence, 2023

Harm Reduction View: Dr. Kyle Gillett

“If it gets FDA approval, it’ll become one of the safest pharmacologic tools for fat loss. Until then, self-experimentation carries sourcing and dosing risks.” — The Anabolic Doc Podcast Ep. 421 (08:33)

Patient Community Consensus

Top-reported benefits (r/ObesityTreatment, n=441 threads): appetite control (+72%), reduced emotional eating (+58%), and sustainable lifestyle integration — especially when combined with semaglutide.

When to Stop or Consult a Doctor

Discontinuation Triggers

39.  Persistent vomiting (>72 hours)

40.  Signs of dehydration or electrolyte imbalance

41.  Severe abdominal pain (rule out pancreatitis)

Medical Consultation Recommended If

42.  History of medullary thyroid carcinoma

43.  Personal or family history of Multiple Endocrine Neoplasia Type 2 (MEN2)

44.  Taking insulin or other glucose-lowering agents

As advised by Dr. Tina Vilsbøll on The Diabetic Investor Podcast Ep. 112.

Whether you are exploring amylin-based appetite suppressants, GLP-1 receptor agonists, or dual-agonist peptides for weight management, the quality of your source determines your outcomes. Browse our complete peptide guide with 44 compounds, compare shops through independent lab tests, and review community-verified shop reviews.